Compare Crispr Therapeutics AG (CRSP) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Keysight Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $50.95 (market cap $5.06B), while Keysight Technologies Inc trades at $380.3 (market cap $64.93B). The key difference: Keysight Technologies Inc is far larger — about 12.8× Crispr Therapeutics AG's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Keysight Technologies Inc for 56 Days on average.
| CRSP | KEYS | |
|---|---|---|
Market Cap | $5.06B | $64.93B |
Volume | 1,678,371 | 1,037,588 |
Sector | Health | Technology |
52-Week High | $74.92 | $387.90 |
52-Week Low | $44.34 | $159.49 |
Typical Hold Time | 77 Days | 56 Days |
Enterprise Value | $3.48B | $65.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
Keysight Technologies (KEYS) trades at $374.66, down 3.41% on the day but remains in a bullish technical trend with strong analyst support. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 surpassing the $2.48 estimate. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
Outlook is positive driven by AI and 6G demand, but high valuation multiples pose a risk. The consensus price target of $416.63 implies 11% upside. Key risks include supply constraints and competitive pressures in the semiconductor testing space. Institutional sentiment remains bullish with 81% of analysts rating the stock a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
